Focal Segmental Glomerulosclerosis Market Primary Research, Secondary Research, Size, Trends and Forecast by 2025
The focal segmental glomerulosclerosis (FSGS) market
is highly competitive due to presence of numerous large players and presence of local players. Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., and Retrophin, Inc.
The global focal segmental glomerulosclerosis (FSGS) market will likely see continued changes in its contours with the successful launch of pipeline products in the next couple of years.
As per a report by Transparency Market Research, the global focal segmental glomerulosclerosis (FSGS) market will likely rise at a solid 8.0% CAGR over the course of the forecast period from 2017 to 2025. Expanding at this pace, the market which was worth US$7.82 bn in 2016, is projected to attain a value of US$15.83 bn by 2025-end.
Based upon the type of disease, the market can be bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Between the two, the primary focal segmental glomerulosclerosis held a substantial 79.8% share in the market in 2016.
Growing awareness about the disease and its management is at the forefront of driving growth in the segment.
North America, of them, leads with a dominant share on the back of a properly structured healthcare industry and availability of reimbursement policies with wider coverage.
Get Brochure of the Report @www.transparencymarketresearch.com/sample/…p_id=31505
Request For Covid19 Impact Analysis –www.transparencymarketresearch.com/sample/…p_id=31505
Rising Instances of the Rare Disease Boosts Demand in Market
Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death.
FSGS advances much more swiftly than diabetic nephropathy
. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease.
Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.
“Focal segmental glomerulosclerosis affects approximately 210,200 patients worldwide with 14,000 to 16,000 new cases every year. This has been a major growth driver in the market.
Efforts by NGOs to Generate Awareness about FSGS to Bolster Market
Apart from the rising cases of the medical condition, other factors that can benefit the market are efforts by non-government organizations to increase awareness and increasing allocation towards research on rare diseases. NephCure Kidney International, The Kidney & Urology Foundation of America (KUFA), EURORDIS, and The National Organization for Rare Disorders (NORD) are some of the non-governmental organizations that are helping out patients with focal segmental glomerulosclerosis and generating awareness about the disease.
Besides, research in the renal treatment field have resulted in several new drugs being developed and approved every year.
Rising kidney transplants and dialysis procedures are other factors promoting the said market. As per the analyst, the market holds out a lot of opportunity due to a limited number of pipeline products at present.
This information is included the report titled, “Focal Segmental Glomerulosclerosis (FSGS) Market (Disease Type – Primary Focal Segmental Glomerulosclerosis and Secondary Focal Segmental Glomerulosclerosis; Disease Management – Diagnosis (Kidney Biopsy and Creatine Test) and Treatment (Drug Therapy, Dialysis, and Kidney Transplant) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025”
Read our Case study at : www.transparencymarketresearch.com/casestu…g-start-up
The focal segmental glomerulosclerosis (FSGS) market is segmented as below:
Global Focal Segmental Glomerulosclerosis (FSGS) Market, by Disease Type
- Primary Focal Segmental Glomerulosclerosis
- Secondary Focal Segmental Glomerulosclerosis
Global Focal Segmental Glomerulosclerosis (FSGS) Market, by Disease Management
- Kidney Biopsy
- Creatine Test
- Drug Therapy
- Kidney Transplant
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
More Trending Reports by Transparency Market Research – 1. www.prnewswire.com/news-re…16214.html
Category: Market Research Publishers and Retailers Profile: Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
For more information:
Make an Inquiry about this report HERE!